RAISING THE BAR IN BREAST CANCER CARE

Transcription

1 RAISING THE BAR IN BREAST CANCER CARE Multidisciplinary Approach in Breast Cancer October 20th, 2017 Dan Hotel, Tel-Aviv HER2+ ER+ HER2- TNBC luminal B luminal A בחסות חברת רוש פרמצבטיקה )ישראל( בע"מ

2 Kimberly L. Blackwell, MD Kimberly L. Blackwell, MD, is a and Assistant Professor of Radiation Oncology at in. She is the Director of Strategic Relations at the Duke Cancer Institute. She is also the Director of the Breast Cancer Program at the Duke Cancer Institute, where she oversees all basic and translational research programs involving breast cancer patients. She received her medical degree at Mayo Clinic Medical School in Rochester, MN. Afterwards, she completed an internal medicine internship and residency and a hematology-oncology fellowship at Duke University Medical School. Her clinical and research interests include various topics in breast cancer, such as angiogenesis, breast cancer in younger women, endocrine therapy, novel HER2 therapies, breast cancer vaccines, and other experimental therapeutics for breast cancer. As board certified in medical oncology, she maintains an active clinical practice of over 500 patients and has served as the PI or co-pi on over 50 clinical trials in breast cancer, including pivotal phase II and III trials that led to the approval of lapatinib for the treatment of HER2-positive breast cancer, and the recently published EMILIA trial assessing the safety and efficacy of T-DM1 in HER2-positive metastatic breast cancer. She is a past recipient of the Duke University Specialized Program of Research Excellence (SPORE) in breast cancer Young Investigator Award, the Duke Cancer Center Malek Family Award for outstanding cancer investigation, and the Joseph Greenfield Award for Research Mentorship. She serves on the national Scientific Advisory Board of the Susan G Komen for the Cure, the CALGB Correlative Science Core Committee, as well as the Steering Committee Chair for CHAMBER (Collaborations for HeAlth IMprovements in HER2+ Breast CancER). She has authored or co-authored over 60 articles or book chapters appearing in journals such as Clinical Cancer Research, Journal of Clinical Oncology, Cancer, Radiation Research, and Molecular Cancer Therapeutics.

3 Friday, 20 th October :30-09:00 Reception 09:00-09:10 Opening Remarks 09:10-11:20 Panel Discussion - Part 1 Moderator: Panel: Dr. Noa Efrat Ben-Baruch Head, Israeli Breast Cancer Group Head, Department of Oncology Kaplan Medical Center Prof. Bella Kaufman Head, Breast Oncology Institute Sheba Medical Center Dr. Shani Paluch-Shimon Director, Breast Oncology Unit Department of Oncology Shaare Zedek Medical Center Dr. Moshe Carmon Head of Breast Unit Shaare Zedek Medical Center Dr. Yonina Tova Radiation Oncologist Assuta Medical Centers 9:10-10:00 The evolution of HER2-Positive Early Breast Cancer Treatment 10:00-10:40 Optimizing Treatments in Triple Negative Breast Cancer Dr. Ofer Rotem Davidoff Center Rabin Medical Center 10:40-11:20 Optimal Sequencing Therapy in HER2- Positive Metastatic Breast Cancer Dr. Shlomit Strulov Shachar Rambam Health Care Campus 11:20-11:55 Coffee Break

4 Friday, 20 th October 2017 (continued) 11:55-13:15 Panel Discussion - Part 2 Moderator: Panel: Dr. Noa Efrat Ben-Baruch Head, Israeli Breast Cancer Group Head, Department of Oncology Kaplan Medical Center Prof. Rinat Yerushalmi Director, Breast Cancer Unit Davidoff Center Rabin Medical Center Dr. Einav Gal-Yam Head, Ambulatory Care Unit Deputy Head, Breast Cancer Unit Institute of Oncology Sheba Medical Center, Tel Hashomer Prof. Tamar Safra Medical Oncology & Radiotherapy Head, Onco-Gynecology Service Tel Aviv Sourasky Medical Center 11:55-12:35 The Optimal Endocrine Therapy in Premenopausal Woman with Early Breast Cancer Dr. Ella Evron Head, Breast Cancer Unit Tel Aviv Sourasky Medical Center 12:35-13:15 Selection and Sequencing of Therapy for Patients with ER-Positive, HER2-Negative Metastatic Breast Cancer Dr. Margarita Tokar Soroka University Medical Center

5